What Happens When You Stop Ozempic and GLP-1? Weight Regain Data

GLP-1 receptor agonists (GLP-1 RA) — such as Ozempic, Wegovy, Mounjaro, Saxenda, and Rybelsus — have gained an important place in obesity treatment in recent years. The common question on many patients' minds is this: "Do you regain weight after stopping Ozempic?" The weight regain that occurs after these medications are discontinued has become a critical issue for both patients and physicians. In this article, we look at current clinical data and discuss the options for lasting weight management.

---

What Is GLP-1 RA?

GLP-1 receptor agonists are medications that slow gastric emptying, reduce appetite, and regulate insulin secretion. The most frequently discussed molecules in this class in Turkey are semaglutide (Ozempic, Wegovy, and its oral form Rybelsus), tirzepatide (Mounjaro — actually a dual GLP-1/GIP agonist), and liraglutide (Saxenda). Initially developed for the treatment of type 2 diabetes, these medications have also found widespread use in obesity management.

The response to these medications varies considerably from person to person. Both efficacy and side-effect profiles show individual differences. The decision to use them must be made together with your specialist physician.

---

Clinical Data: What Happens When You Stop?

A comprehensive meta-analysis published in 2025 provides strong evidence on what happens when Ozempic and similar GLP-1 RAs are discontinued:

Study: 18 randomized controlled trials, a total of 3,771 patients Journal: EClinicalMedicine (Lancet group) — 2025 PMID: 41399474

Key Findings

• An average of +5.63 kg regained was observed after discontinuation of the medication
• The regain became evident within 12 months after the medication was stopped
• A significant portion of the weight lost during the medication period was regained

These data show that the efficacy of GLP-1 RA is largely dependent on continuous use.

Results vary from person to person. These data are group averages.

Second piece of evidence: the 2026 systematic review published in BMJ

This picture is also consistent with a broader review. The 2026 systematic review published in BMJ (West et al.) brought together 37 studies and 9,341 participants. In the GLP-1 subgroup of the review:

• An average of approximately 9.9 kg regained was reported in the first year after discontinuation (versus an average loss of approximately 14.7 kg).
• About half of users stop the medication within 12 months.

The two studies point in the same direction: while the 18-RCT meta-analysis shows an average of +5.63 kg regained after discontinuation, the broader BMJ 2026 review paints a picture of more pronounced regain in the GLP-1 subgroup in the first year (~9.9 kg) and a high discontinuation rate. The difference in the numbers stems from differences in the included studies and follow-up conditions; the common message is that the effect depends on continuous use and behavior change. Results vary from person to person.

---

Why Is Weight Regained?

GLP-1 RA works mainly through its effects on appetite and metabolism. When the medication is stopped:

1. Hormonal balance changes: The appetite-regulating effect disappears
2. Behavioral change may not be permanent: If healthy eating habits have not been sufficiently established during the medication period, the return to old patterns accelerates once the medication is stopped
3. Bodily adaptation: Metabolism may have slowed in response to prolonged caloric restriction

These mechanisms underscore how critical behavior change is, alongside medication, in weight management.

---

Is the Gastric Balloon Different?

The gastric balloon and GLP-1 RA work through different mechanisms:

Feature	GLP-1 RA	Allurion Gastric Balloon
Mechanism	Hormonal (appetite, insulin)	Volumetric (early satiety)
Duration	Requires continuous use	16 weeks, one-time
Behavior change	Dependent on medication	Active during the program
After 1 year	Regain common once medication is stopped	1 year after balloon removal, 95% of patients maintained their weight loss (Caballero et al., n=522; PMID 40676353)

Caballero and colleagues' study of 522 patients showed that 1 year after the Allurion balloon was passed, 95% of patients maintained their weight loss (Obes Surg 2025, PMID: 40676353).

The main reason for this difference: the Allurion program places behavioral habit change at its core during an intensive 16-week process. Digital monitoring, nutrition coaching, and physician follow-up support this transformation.

---

The Combination Option

Protocols in which GLP-1 RA and the Allurion program are used together are under investigation. According to Allurion-Eli Lilly preliminary results from February 2026 (n=76, press release, peer-review pending), the combination of a low-dose GLP-1/GIP receptor agonist + Allurion achieved 23% TBWL.

The theory behind this protocol is as follows: habits become established during the 16 weeks the balloon is active; after this period, the GLP-1 RA dose can be reduced or stopped — because balloon support is provided during the bridge period, the risk of regain is reduced.

The combination protocol is still in the research stage. We recommend that you discuss this in detail with your physician.

---

What You Need to Know If You Are Using GLP-1 RA

• Do not stop the medication on your own: Plan the dose-reduction or discontinuation process with your physician
• Regain is not inevitable: Outcomes can be more durable when an investment is made in behavior change
• Make a long-term plan: Weight management is sustained not with a single tool but with an integrated approach

---

Conclusion

When GLP-1 RA is stopped, an average of +5.63 kg regained is seen (meta-analysis, 18 RCTs, 3,771 patients). This shows that obesity treatment requires a long-term process and that medication therapy alone is often not sufficient.

Program-supported approaches that place behavior change at their core — such as Allurion — may offer more sustainable results.

Continue reading:

• GLP-1 + Gastric Balloon Combined Treatment →
• Swallowable Gastric Balloon 2026 Guide →
• Clinical Evidence →
• Calculate BMI →

---

This content is for general informational purposes. Always consult your physician regarding the use or discontinuation of GLP-1 RA.

---

The Regain Mechanism: Why Does It Happen?

GLP-1 receptor agonists work by suppressing the appetite centers in the brain. When the medication is stopped, this suppression is lifted and physiological hunger signals return. According to "set point" theory, the body tends to return to its previous weight.

This mechanism shows that the weight regain after medication discontinuation has not only a behavioral but also a physiological component. Data compiled from randomized controlled trials reported that a significant portion of the weight lost during the medication period was regained within 12 months following GLP-1 RA discontinuation (meta-analysis, 18 RCTs, 3,771 patients; PMID 41399474). While this tendency is commonly observed, it is not absolute and can be reduced with structural support; results vary from person to person.

---

Combined Approach: Balloon + GLP-1

The combined use of the two methods is increasingly being investigated:

• Allurion + GLP-1: The balloon provides mechanical satiety while GLP-1 adds appetite suppression
• Preliminary clinical data support combination approaches in which the balloon and GLP-1 RA are evaluated together through complementary mechanisms (PMID 41212463); these data are preliminary in nature, and suitability is determined by physician evaluation.
• GLP-1/GIP + Allurion combination, preliminary results (n=76): An average of 23% total body weight loss (TBWL) was reported with the combination of a low-dose GLP-1/GIP receptor agonist and Allurion. For comparison, balloon monotherapy in clinical trials showed an average of approximately 15% TBWL (Ienca 2020, n=1770, 14.9%; PMID 32279182). This combination data is preliminary in nature (press release, peer-review pending); suitability is determined by physician evaluation.

---

What Should You Do After Stopping GLP-1?

If you are using Ozempic, Wegovy, or Mounjaro and are planning to stop, here are the strategies experts recommend:

1. Structured program: Behavior change should be established before stopping the medication — programs such as the balloon build this foundation
2. Transition planning: GLP-1 should be stopped by tapering gradually; abrupt discontinuation can lead to faster regain
3. Follow-up system: Digital monitoring such as the Allurion Virtual Care Suite can also be used in the post-medication period

---

Risk-Benefit Assessment

	GLP-1 Monotherapy	Allurion Program	Combination
Weight loss	~15–20% during the medication period (literature)	~15% TBWL in clinical trials (Ienca 2020, n=1770, 14.9%; PMID 32279182)	~23% TBWL (preliminary data, peer-review pending)
Regain risk	High (once medication is stopped)	Dependent on behavior change	Under investigation
Duration	Uncertain (chronic?)	6-month program	Depends on the protocol
Cost	Recurring monthly	One-time	Sum of the two

---

FAQ — GLP-1 and Weight

How much weight is regained when GLP-1 is stopped? According to meta-analysis data (18 RCTs, 3,771 patients; PMID 41399474), an average of +5.63 kg regained was reported within 12 months following GLP-1 RA discontinuation. This means that a significant portion of the weight loss achieved during the medication period was regained. The degree of regain varies from patient to patient; the individual course depends on physician evaluation.

Do you regain weight after stopping Ozempic? Since Ozempic (semaglutide) is a GLP-1 receptor agonist, the above data also apply to this molecule. In clinical data, weight regain after discontinuation is commonly seen; the 2026 systematic review published in BMJ reported an average of approximately 9.9 kg regained in the first year in the GLP-1 subgroup, and that about half of users stop the medication within 12 months. A similar tendency is expected with other medications such as Wegovy and Mounjaro. Results vary from person to person; tapering the dose gradually under physician supervision and establishing behavior change can reduce the risk.

Can GLP-1 and the balloon be used together? Some physicians apply a combined protocol. This decision requires individual medical evaluation — talk to your physician.

Can a balloon be placed before stopping GLP-1? It depends on the protocol. At some clinics, a balloon transition strategy is planned for patients completing GLP-1 treatment.

Is it possible to completely prevent weight regain? No method provides a 100% guarantee. Lasting weight loss must be supported by behavior change.

---

Continue reading:

• Gastric Balloon + GLP-1 Combination →
• Clinical Evidence →
• How Does It Work? →

---

This content is for general informational purposes. Always consult your physician regarding the use or discontinuation of GLP-1 RA.

---

The Period After GLP-1: Structural Support

The common characteristics of patients who make a successful transition after stopping the medication:

1. Having established eating habits during the treatment period: GLP-1 suppresses appetite; those who use this window for new habits achieve better results after the medication
2. Body image and attitude change: Psychosocial support programs that follow weight loss increase long-term success
3. Structural follow-up: Digital monitoring systems such as Allurion can also be used in the post-GLP-1 period

If you are considering starting or stopping GLP-1, first make your transition plan with your physician.

---

Evaluate It Within a Program Framework

Regardless of the choice of medication or combination, long-term success comes from being tied to a program. Allurion's 6-month integrated structure — capsule, digital monitoring, nutritional support — provides this framework.

If you have used GLP-1 and need ongoing support, structured programs of this kind can play an important role during the transition period. Plan the most appropriate sequence together with your physician.

An Authorized Clinic in a City Near You

You can have the Allurion program performed at more than 60 authorized clinics throughout Turkey. For clinics in major cities:

• Gastric balloon clinic in Istanbul →
• Gastric balloon clinic in Ankara →
• Gastric balloon clinic in Izmir →
• Gastric balloon clinic in Antalya →
• Find a specialist in all cities →